نتایج جستجو برای: gvhd

تعداد نتایج: 4940  

Journal: :Journal of immunology 2000
M R van Den Brink E Moore K J Horndasch J M Crawford J Hoffman G F Murphy S J Burakoff

The Fas/Fas ligand (FasL) pathway is involved in a variety of regulatory mechanisms that could be important for the development of graft-vs-host disease (GVHD) after bone marrow transplantation (BMT), such as cytolysis of target cells by cytotoxic T cells, regulation of inflammatory responses, peripheral deletion of autoimmune cells, costimulation of T cells, and activation-induced cell death. ...

2011
John D. Roback Andrew T. Gewirtz Edmund K. Waller Alton B. Farris Malefa L. Tselanyane Ebenezer David Mohammad S. Hossain David L. Jaye Brian P. Pollack

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in patients treated with allogeneic hematopoietic stem cell transplantation (HSCT). Posttransplant immunosuppressive drugs incompletely control GVHD and increase susceptibility to opportunistic infections. In this study, we used flagellin, a TLR5 agonist protein (∼50 kDa) extracted from bacterial flagella, as a novel e...

Journal: :Pediatrics 1999
P Mehta A Kedar J Graham-Pole S Skoda-Smith J R Wingard

Thalidomide has one of the most notorious drug histories because of its teratogenicity. Its widespread use in the 1960s led to a worldwide epidemic of phocomelia in inborns; this in turn led to its complete ban in most of the world. However, it has now been licensed for selected indications including graft-versus-host-disease (GVHD) after bone marrow transplantation, wasting associated with tub...

Journal: :The Journal of clinical investigation 1998
W J Murphy L A Welniak D D Taub R H Wiltrout P A Taylor D A Vallera M Kopf H Young D L Longo B R Blazar

Graft-versus-host disease (GVHD), in which immunocompetent donor cells attack the host, remains a major cause of morbidity after allogeneic bone marrow transplantation (BMT). To understand the role of cytokines in the pathobiology of GVHD, we used cytokine knockout (KO) mice as a source of donor T cells. Two different MHC-disparate strain combinations were examined: BALB/c (H2(d)) donors into l...

Journal: :Blood 1990
T P Loughran K Sullivan T Morton C Beckham M Schubert R Witherspoon G Sale J Sanders L Fisher H Shulman

We prospectively evaluated 169 patients with a number of screening studies performed between 71 to 121 days after allogeneic marrow transplantation to detect the development of chronic graft-versus-host disease (GVHD). Group 1 patients (n = 78) were asymptomatic and had normal physical examinations at the time of screening and, with a minimum of 8 years follow-up, have not developed chronic GVH...

Journal: :Blood 1998
B R Dey Y G Yang G L Szot D A Pearson M Sykes

We have recently made the paradoxical observation that a single injection of recombinant murine interleukin-12 (IL-12) on the day of bone marrow transplantation (BMT) inhibits graft-versus-host disease (GVHD) in lethally irradiated mice receiving fully major histocompatability complex (MHC)-mismatched bone marrow and spleen cells. We have now examined the mechanism of this effect of IL-12 on ac...

Journal: :Blood 2011
Thomas Luft Sascha Dietrich Christine Falk Michael Conzelmann Michael Hess Axel Benner Frank Neumann Berend Isermann Ute Hegenbart Anthony D Ho Peter Dreger

Acute graft-versus-host disease (GVHD) is a major complication of allogeneic stem cell transplantation (SCT) and can be readily controlled by systemic high-dose steroids in many patients. However, patients whose GVHD is refractory to this therapy have a poor prognosis. Refractory patients have ongoing end-organ damage despite effective immunosuppression with second-line regimens, suggesting pat...

2016
Erica Dander Paola De Lorenzo Barbara Bottazzi Paola Quarello Paola Vinci Adriana Balduzzi Francesca Masciocchi Sonia Bonanomi Claudia Cappuzzello Giulia Prunotto Fabio Pavan Fabio Pasqualini Marina Sironi Ivan Cuccovillo Roberto Leone Giovanni Salvatori Matteo Parma Elisabetta Terruzzi Fabio Pagni Franco Locatelli Alberto Mantovani Franca Fagioli Andrea Biondi Cecilia Garlanda Maria Grazia Valsecchi Attilio Rovelli Giovanna D'Amico

Acute Graft-versus-Host Disease (GvHD) remains a major complication of allogeneic haematopoietic stem cell transplantation, with a significant proportion of patients failing to respond to first-line systemic corticosteroids. Reliable biomarkers predicting disease severity and response to treatment are warranted to improve its management. Thus, we sought to determine whether pentraxin 3 (PTX3), ...

2012
Hui Wang Yanping Yang Guanjun Wang Shumei Wang Beow Yong Yeap Megan Sykes Yong-Guang Yang

Delayed administration of donor lymphocyte infusion (DLI) to established mixed chimeras has been shown to achieve anti-tumor responses without graft-vs.-host disease (GVHD). Herein we show that de novo donor BM-derived T cells that are tolerant of the recipients are important in preventing GVHD in mixed chimeras receiving delayed DLI. Mixed chimeras lacking donor BM-derived T cells developed si...

2017
Sabine Westphal Aleixandria McGeary Sandra Rudloff Andrea Wilke Olaf Penack

Allogeneic hematopoetic stem cell transplantation (allo-HSCT) is a standard treatment for leukemia and other hematologic malignancies. The major complication of allo-HSCT is graft-versus-host-disease (GVHD), a progressive inflammatory illness characterized by donor immune cells attacking the organs of the recipient. Current GVHD prevention and treatment strategies use immune suppressive drugs a...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید